COVID-19 Antiviral Drug Development

Manoppiravir2 Wirefare Molecular Structure.png

Manoppiravir (MnP)

IUPAC name: (3E,4S)-3-{2-[(1S,4aS,5R,6S,8aS)-7-amino-4-chloro-3-fluoro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one

Chemical Properties

Formula:C20H29NFClO5

Exact Mass:417.17

Mol.Wt.:417.9

Elem.Anal.:C,57.48

O,19.14

Cl,8.48

F,4.55

N,3.35

H,6.99

m/z:417.2(100.0%)

419.2(35.4%)

418.2(22.5%)

420.2(7.6%)

421.2(1.1%)

Patents Information

Inventor: Manop Kaewkoi
Country: Thailand
Publication: July 2021

Abstract:

The coronavirus COVID-19 pandemic infectious disease caused by a novel coronavirus (SARS-CoV-2) is the defining global health crisis. Since its emergence in Asia in 2019, the virus has spread to every continent as a result, up to 183 million people have been infected worldwide and 3.9  million people have died (*update 5 July 2021). Here we are developing new effectives antiviral active ingredients (API) for new preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19) Our research team using quantum biology, chemical principle and artificial Intelligent to research molecular structures, models, synthesis process, therapeutics of new effective COVID-19 antiviral drugs.

Research Timeline

April 2021 - May 2021

June 2021-July 2021

July 2021 - October 2021

1) Design COVID-19 drug's new effective antiviral active ingredient (API) molecular structure, Model and Biosynthesis processes. 
2) Synthesis prototype of COVID-19 drug's new effective antiviral active ingredient (API).

1) Patent Registration of API and Manoppiravir Antiviral Drug.

2) Study Cytotoxicity and Anti-SARS-CoV-2 of Manoppiravir.

3) Clinical Study.

1) WHO and FDA Registration.

2) Pilot scale production.

3) Industrial scale production.

BRAIN RESOURCES